


REIVINDICACIONES MODIFICADAS

1. Compuesto que tiene la estructura:



O una sal farmacéuticamente aceptable del mismo, donde,

a) ABM es:



Donde:

W¹ es arilo o heteroarilo, cada uno independientemente sustituido con uno o más de H, halógeno, hidroxilo, nitro, CN, alquilo C₁₋₆ sustituido por 1 o más de halógeno o alcoxilo C₁₋₆, o alcoxilo C₁₋₆ opcionalmente sustituido con uno o más halógenos;

Y³, Y⁴ y Y⁵ son cada uno independientemente O, NR^{Y2}, CR^{Y1}R^{Y2} o C=O

Q es un anillo alicíclico de 6 miembros opcionalmente sustituido con hasta 6 R^Q, cada R^Q, es independientemente H, halógeno, alcoxilo C₁₋₆, alquilo C₁₋₆ opcionalmente sustituido con 1 o más de halógeno o alcoxilo C₁₋₆;

R^{Y1}, R^{Y2} son cada uno independientemente H, halógeno, alcoxilo C₁₋₆ o alquilo C₁₋₆ opcionalmente sustituido con 1 halógeno o alcoxilo C₁₋₆;

W² es arilo opcionalmente sustituido con 1-4 R^{W2}, o un heteroarilo opcionalmente sustituido con 1-4 R^{W2};

Cada R^{W2} es independientemente H, halógeno, OH, NR^{Y1}R^{Y2}, CN, alquilo C₁₋₆ opcionalmente sustituido con 1 o más F, o O-alquilo C₁₋₃ sustituido con 1 o más


-F⁻; y

----- es el punto de unión del ABM al grupo de unión químico (L);

- b) L es un grupo de unión químico que está covalentemente enlazada al ABM y al CLM y tiene la estructura química $-(A^L)_q-$, en donde, q es un número entero de 1 a 20, cada A^L se selecciona del grupo que consiste en $CR^{L1}R^{L2}$, O, S, SO_2 , NR^{L3} , CO, $CR^{L1}=CR^{L2}$, $C\equiv C$, cicloalquilo C_{3-11} opcionalmente sustituido con 1-6 R^{L1} , espirocicloalquilo C_{5-13} opcionalmente sustituido con 1-9 R^{L1} , heterociclilo C_{3-11} sustituido con 1-6 grupos R^{L1} , espiroheterocicloalquilo C_{5-13} opcionalmente sustituido con 1-8 grupos R^{L1} , arilo opcionalmente sustituido con 1-6 grupos R^{L1} y heteroarilo opcionalmente sustituido con 1-4 grupos R^{L1} ; y

R^{L1} , R^{L2} , R^{L3} , son, cada uno independientemente, H, alquilo C_{1-8} , O-alquilo C_{1-8} , NH-alquilo C_{1-8} , N(alquil C_{1-8})₂, cicloalquilo C_{3-11} , arilo, heteroarilo, heterociclilo C_{3-11} , O-cicloalquilo C_{3-8} , NH-cicloalquilo C_{3-8} , N(cicloalquil C_{3-8})₂, N(cicloalquil C_{3-8})(alquil C_{1-8}), OH, NH_2 , COalquilo C_{1-8} , CO_2H , halógeno, CN, CF_3 , CHF_2 , CH_2F , NO_2 , $CONH$ (alquil C_{1-8}), CON (alquil C_{1-8})₂, o R^{L1} y R^{L2} se unen para formar un resto de cicloalquilo o heterociclilo; y

- c) CLM es



en donde

W se selecciona del grupo que consiste en CH_2 , CHR, C=O, NH, y N-alquilo;

Cada X es O;

Z es O;

G es H;


Q_1 , Q_2 , Q_3 , y Q_4 son cada una independientemente N, CH o CR;

A es H;

n es un entero de 1 a 4; R se selecciona del grupo que consiste en -CONR'R'', -O', -NR'R'', -CR'R''-, -CR'NR'R''-, arilo, heteroarilo, alquilo C₁₋₆, cicloalquilo, heterocicloalquilo, -Cl, -F, -Br, -I, -CF₃, -CN, -NR'SO₂NR'R'', -NR'CONR'R'', -CONR'COR'', -SO₂NR'COR'', -NO₂, -CO₂R', -CR'=CR'R'', -C≡CR', -R'NR'R'', y -OCF₃, y en donde un R se modifica para estar covalentemente unido al grupo de elemento de unión (L);

R' y R'' se seleccionan cada uno independientemente del grupo que consiste en un enlace, H, alquilo C₁₋₆, cicloalquilo, arilo, heteroarilo y heterociclilo; y  representa un enlace que puede ser estereoespecífico ((R) o (S)) o no estereoespecífico.

2. El compuesto de la reivindicación 1 o una sal farmacéuticamente aceptable de este, donde W¹ es:





Donde:

R₂₂ es un halógeno, alquilo C₁₋₆ opcionalmente sustituido con uno o más halógenos, CN, o nitro; y


Cada R₂₃ es independientemente H, halógeno, alquilo C₁₋₆ opcionalmente sustituido con 1 o más halógeno, CN o nitro.


3. El compuesto de la reivindicación 1, o una sal farmacéuticamente aceptable del






4. El compuesto de cualquiera de las reivindicaciones 1 a 3, o una sal farmacéuticamente aceptable del mismo, donde W^2 se selecciona del grupo que





5. El compuesto de cualquiera de las reivindicaciones 1-4, o una sal farmacéuticamente aceptable del mismo, donde el CLM tiene una estructura química representada por:



Donde:

W es CH₂ o C=O;

A es H;


R se selecciona del grupo que consiste en -CONR'R'', -O', -NR'R'', -CR'R''-, -CR'NR'R''-, arilo, heteroarilo, alquilo C₁₋₆, cicloalquilo, heterocicloalquilo, -Cl, -F, -Br, -I, -CF₃, -CN, -NO₂, -CO₂R', -CR'=CR'R'', -C≡CR', R'NR'R'' y -OCF₃, donde R está modificado para unirse covalentemente al grupo de unión (L);












R' y R'' son cada uno independientemente seleccionados del grupo que consiste en un enlace H, alquilo C₁₋₆, cicloalquilo, arilo, heteroarilo, y heterociclilo; y






~~~~~ representa un enlace que puede ser estereoespecífico ((R) o (S)) o no estereoespecífico; y

n es un entero de 1 a 4, donde un solo R está modificado para estar unido covalentemente al grupo de elemento de unión químico (L).

























6. El compuesto según cualquiera de las reivindicaciones 1-5, o una sal farmacéuticamente aceptable del mismo, donde el grupo de elemento de unión químico (L) comprende un grupo representado por una estructura seleccionada del grupo que consiste en:






























































X = H, F























donde:


R del grupo de elemento de unión químico es H, metilo o etilo;


X del grupo de elemento de unión químico es H o F; y

cada m, n, o, p, q, y r del grupo de elemento de unión químico es independientemente 0, 1, 2, 3, 4, 5, o 6, con la condición de que cuando el número es cero, no hay enlace N-O u O-O.



7. El compuesto según cualquiera de las reivindicaciones 1-5, o una sal farmacéuticamente aceptable del mismo, donde el grupo de elemento de unión químico (L) es seleccionado del grupo que consiste en:















8. El compuesto según la reivindicación 1, donde el compuesto es:


















(417),








(418),














(542),




(543),




(547),









(548),










(549),



(559),








(625), o

una sal farmacéuticamente aceptable del mismo.

9. El compuesto según la reivindicación 1, o una sal farmacéuticamente aceptable del mismo, donde el ABM es:



donde:

$R^{Q2}$  es un H, halógeno,  $CH_3$ , o  $CF_3$ ; y

$R^{Q3}$  es un H, halógeno, hidroxilo, nitro, CN, alquilo  $C_{1-6}$  opcionalmente sustituido con 1 o más halógeno, o alcoxilo  $C_{1-6}$  opcionalmente sustituido con 1 o más halógenos;

$Y^3$ ,  $Y^4$ , y  $Y^5$  son cada una independientemente O,  $NR^{Y2}$ ,  $CR^{Y1}R^{Y2}$ , o  $C=O$ ;

$R^{Y1}$  y  $R^{Y2}$  son cada uno independientemente H o alquilo  $C_{1-6}$  opcionalmente sustituido con 1 o más halógenos; y

X es N o CH.

10. El compuesto de la reivindicación 9, o una sal farmacéuticamente aceptable del mismo, donde:

R<sup>Q2</sup> es halógeno;

R<sup>Q3</sup> es un CN;


Y<sup>3</sup> es O;



Y<sup>4</sup> es NH;

Y<sup>5</sup> es C=O; y


X es N o CH.

11. El compuesto según la reivindicación 1, o una sal farmacéuticamente aceptable del mismo, donde el ABM es:






12. El compuesto según la reivindicación 1, o una sal farmacéuticamente aceptable del mismo, donde el ABM es:



13.El compuesto de cualquiera de las reivindicaciones 1-4, o una sal farmacéuticamente aceptable del mismo, donde el CLM tiene una estructura química representada por:



donde:

W es C=O;


A es H;




R se selecciona del grupo que consiste en -CONR'R'', -OR', -NR'R'', -CR'R''-, heterocicloalquilo, -Cl, -F, -CF<sub>3</sub>, -CN, -NR'SO<sub>2</sub>NR'R'', -NR'CONR'R'', -CONR'COR'', -SO<sub>2</sub>NR'COR'', -NO<sub>2</sub>, -CO<sub>2</sub>R', -R'NR'R'', y -OCF<sub>3</sub>, donde un R está modificado para unirse covalentemente con el grupo de elemento de unión químico (L);




R' y R'' son cada uno independientemente seleccionados del grupo que consiste en un enlace, H, alquilo C<sub>1-6</sub>, cicloalquilo, arilo, heteroarilo, y heterociclilo; y




 representa un enlace que puede ser estereoespecífico ((R) o (S)) o no estereoespecífico; y n es 2, donde un R está modificado para unirse covalentemente con el grupo de elemento de unión químico (L).



14. El compuesto de la reivindicación 1, donde el compuesto es:











una sal farmacéuticamente aceptable del mismo.

15. Una composición farmacéutica que comprende una cantidad efectiva de un compuesto de cualquiera de reivindicaciones 1-14, o una sal farmacéuticamente aceptable del mismo, y un portador farmacéuticamente aceptable.